Literature DB >> 21670978

Progress on plague vaccine development.

Jason A Rosenzweig1, Olufisayo Jejelowo, Jian Sha, Tatiana E Erova, Sheri M Brackman, Michelle L Kirtley, Cristina J van Lier, Ashok K Chopra.   

Abstract

Yersinia pestis (YP), the gram-negative plague bacterium, has shaped human history unlike any other pathogen known to mankind. YP (transmitted by the bite of an infected flea) diverged only recently from the related enteric pathogen Yersinia pseudotuberculosis but causes radically different diseases. Three forms of plague exist in humans: bubonic (swollen lymph nodes or bubos), septicemic (spread of YP through the lymphatics or bloodstream from the bubos to other organs), and contagious, pneumonic plague which can be communicated via YP-charged respiratory droplets resulting in person-person transmission and rapid death if left untreated (50-90% mortality). Despite the potential threat of weaponized YP being employed in bioterrorism and YP infections remaining prevalent in endemic regions of the world where rodent populations are high (including the four corner regions of the USA), an efficacious vaccine that confers immunoprotection has yet to be developed. This review article will describe the current vaccine candidates being evaluated in various model systems and provide an overall summary on the progress of this important endeavor.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21670978     DOI: 10.1007/s00253-011-3380-6

Source DB:  PubMed          Journal:  Appl Microbiol Biotechnol        ISSN: 0175-7598            Impact factor:   4.813


  25 in total

1.  Deletion of Braun lipoprotein and plasminogen-activating protease-encoding genes attenuates Yersinia pestis in mouse models of bubonic and pneumonic plague.

Authors:  Christina J van Lier; Jian Sha; Michelle L Kirtley; Anthony Cao; Bethany L Tiner; Tatiana E Erova; Yingzi Cong; Elena V Kozlova; Vsevolod L Popov; Wallace B Baze; Ashok K Chopra
Journal:  Infect Immun       Date:  2014-03-31       Impact factor: 3.441

2.  High-throughput, signature-tagged mutagenic approach to identify novel virulence factors of Yersinia pestis CO92 in a mouse model of infection.

Authors:  Duraisamy Ponnusamy; Eric C Fitts; Jian Sha; Tatiana E Erova; Elena V Kozlova; Michelle L Kirtley; Bethany L Tiner; Jourdan A Andersson; Ashok K Chopra
Journal:  Infect Immun       Date:  2015-03-09       Impact factor: 3.441

3.  Deletion of the Braun lipoprotein-encoding gene and altering the function of lipopolysaccharide attenuate the plague bacterium.

Authors:  Jian Sha; Michelle L Kirtley; Christina J van Lier; Shaofei Wang; Tatiana E Erova; Elena V Kozlova; Anthony Cao; Yingzi Cong; Eric C Fitts; Jason A Rosenzweig; Ashok K Chopra
Journal:  Infect Immun       Date:  2012-12-28       Impact factor: 3.441

4.  Evaluation of protective potential of Yersinia pestis outer membrane protein antigens as possible candidates for a new-generation recombinant plague vaccine.

Authors:  Tatiana E Erova; Jason A Rosenzweig; Jian Sha; Giovanni Suarez; Johanna C Sierra; Michelle L Kirtley; Christina J van Lier; Maxim V Telepnev; Vladimir L Motin; Ashok K Chopra
Journal:  Clin Vaccine Immunol       Date:  2012-12-12

Review 5.  Bacteriophage T4 nanoparticles for vaccine delivery against infectious diseases.

Authors:  Pan Tao; Jingen Zhu; Marthandan Mahalingam; Himanshu Batra; Venigalla B Rao
Journal:  Adv Drug Deliv Rev       Date:  2018-07-06       Impact factor: 15.470

6.  Cethromycin-mediated protection against the plague pathogen Yersinia pestis in a rat model of infection and comparison with levofloxacin.

Authors:  Jason A Rosenzweig; Sheri M Brackman; Michelle L Kirtley; Jian Sha; Tatiana E Erova; Linsey A Yeager; Johnny W Peterson; Ze-Qi Xu; Ashok K Chopra
Journal:  Antimicrob Agents Chemother       Date:  2011-08-22       Impact factor: 5.191

7.  A Replication-Defective Human Type 5 Adenovirus-Based Trivalent Vaccine Confers Complete Protection against Plague in Mice and Nonhuman Primates.

Authors:  Jian Sha; Michelle L Kirtley; Curtis Klages; Tatiana E Erova; Maxim Telepnev; Duraisamy Ponnusamy; Eric C Fitts; Wallace B Baze; Satheesh K Sivasubramani; William S Lawrence; Igor Patrikeev; Jennifer E Peel; Jourdan A Andersson; Elena V Kozlova; Bethany L Tiner; Johnny W Peterson; David McWilliams; Snehal Patel; Eric Rothe; Vladimir L Motin; Ashok K Chopra
Journal:  Clin Vaccine Immunol       Date:  2016-07-05

8.  A non-invasive in vivo imaging system to study dissemination of bioluminescent Yersinia pestis CO92 in a mouse model of pneumonic plague.

Authors:  Jian Sha; Jason A Rosenzweig; Michelle L Kirtley; Christina J van Lier; Eric C Fitts; Elena V Kozlova; Tatiana E Erova; Bethany L Tiner; Ashok K Chopra
Journal:  Microb Pathog       Date:  2012-10-09       Impact factor: 3.738

Review 9.  Particulate delivery systems for vaccination against bioterrorism agents and emerging infectious pathogens.

Authors:  Yuchen Fan; James J Moon
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-04-01

10.  Intramuscular Immunization of Mice with a Live-Attenuated Triple Mutant of Yersinia pestis CO92 Induces Robust Humoral and Cell-Mediated Immunity To Completely Protect Animals against Pneumonic Plague.

Authors:  Bethany L Tiner; Jian Sha; Duraisamy Ponnusamy; Wallace B Baze; Eric C Fitts; Vsevolod L Popov; Christina J van Lier; Tatiana E Erova; Ashok K Chopra
Journal:  Clin Vaccine Immunol       Date:  2015-10-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.